Novo Nordisk: Power Struggle Leads to Complete Overhaul of the Supervisory Board
Reading Time: 2 minutes
In the Danish pharmaceutical company Novo Nordisk , an unprecedented leadership change is taking place: The chairman of the supervisory board, Helge Lund, and all independent directors will resign in November. The background is a conflict with the Novo Nordisk Foundation, which controls more than 70% of the voting rights through its holding. The foundation had demanded a complete overhaul of the board – the current supervisory board refused to comply. After no agreement was reached, all independent members announced their resignation. The move...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
